复发性铂耐药卵巢癌患者终末期的患者报告结局变化:一项NRG肿瘤学/GOG研究
本研究在前瞻性铂耐药卵巢癌患者中,评估NFOSI-18量表的疾病相关症状-躯体(DRS-P)维度对临床变化的反应性。结果显示,仅完成一次评估的患者DRS-P评分显著低于完成两次或三次评估者,且除神经毒性外,基线评分越高死亡风险越低。结论认为DRS-P能反映疾病进展相关的健康状态变化,且区别于治疗副作用。
要点
- DRS-P评分对铂耐药卵巢癌患者的临床变化有反应性
- 仅完成一次评估者DRS-P评分显著低于完成多次评估者
- 除神经毒性外,基线评分越高死亡风险越低
核心结论
- NFOSI-18的DRS-P维度对临床变化有反应性,可作为卵巢癌疾病进展中健康状态变化的指标,且区别于治疗副作用。
研究设计与样本
- 前瞻性研究,纳入铂耐药卵巢癌患者,在入组时及入组后3个月和6个月收集NFOSI-18及其他FACT量表。
- 比较死亡或提前退出者(假定健康恶化)与完成6个月者(假定疾病稳定)的测量结果。
- 统计分析包括线性混合模型估计组间随时间差异、Cox回归评估患者报告结局与生存概率的关系及效应量。
主要发现
- 仅完成一次评估的患者DRS-P评分显著低于完成两次评估者[低5.9分(2.0-9.8);p < 0.01]。
- 仅完成一次评估的患者DRS-P评分显著低于完成三次评估者[低8.1分(4.8-11.5);p < 0.01]。
- 腹部不适、功能健康、情绪健康和生活质量指标也显著,但治疗副作用不显著。
- 调整年龄、体能状态和疾病状态后,除神经毒性外,所有量表基线评分越高(越好)与死亡可能性降低相关。
临床怎么用
- 可使用NFOSI-18的DRS-P维度监测铂耐药卵巢癌患者疾病进展相关的健康状态变化。
- DRS-P评分变化有助于区分疾病进展与治疗副作用,辅助临床判断。
- 基线患者报告结局评分较高可能提示死亡风险较低,可作为预后参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In a prospective study of platinum-resistant ovarian cancer patients, we examined whether the Disease-related Symptoms-Physical (DRS--P) scale of the NCCN/FACT-Ovarian Cancer Symptom Index-18 (NFOSI-18) is responsive to clinical change in patients estimated by their provider to survive at least six months. METHODS: The NFOSI-18, and other FACT measures, was collected at study entry and 3 and 6 months post-enrollment. Measures were compared for those who died or dropped off study prior to 3 months or prior to 6 months (assumed as health deterioration over time), or those who stayed on study through 6 months (presumed as stable disease over time). Statistical analyses included a fitted linear mixed model for estimating the group differences over time, Cox regression to assess the probability of survival with patient-reported outcomes, and effect size. RESULTS: DRS-P scores of patients who completed only one assessment were significantly lower compared to patients who were able to complete two assessments [5.9 points lower (2.0-9.8); p < 0.01], or three assessments [8.1 points lower (4.8-11.5); p < 0.01]. Measures of abdominal discomfort, functional well-being, emotional well-being, and quality of life were also significant, but treatment side effects were not. Further, in every scale except for neurotoxicity, higher (better) baseline scores were associated with a decreased likelihood of death, after adjusting for age, performance and disease status. CONCLUSION: The NFOSI-18 DRS-P scale is responsive to clinical change. It has potential as an indicator of changing health status with ovarian cancer disease progression, distinct from treatment side effects.
引用
- Wenzel L, Huang HQ, Cella D, et al. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. Gynecol Oncol. 2021. PMID: 34548162. doi:10.1016/j.ygyno.2021.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。